Dapagliflozin (Farxiga, Xigduo) has an important label update – it can now be used in setting of moderate renal impairment (eGFR 45-59 mL/min/1.73 m2). This allows dapagliflozin to be used in a greater number of patients which is especially important in light of its cardiovascular benefit. The link below further describes this label update.
Another important label update is insulin glargine and lixisenatide injection (Soliqua 100/33) now having an indication for persons who had not achieved glycemic target on oral diabetes medication. Remember, Soliqua is a great alternative to basal bolus insulin regimen for persons with Type 2 diabetes. More details are provided in the link below.
Please share your thoughts and subscribe to receive my blogs.
#FDA #label #expansion #dapagliflozin #Soliqua
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.